Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01276587 · ClinicalTrials.gov registry record · Phase 1

Study of Vitamin D in Children With Sickle Cell Disease

A Phase 1 study, sponsored by Gary M Brittenham, MD.

Completed
Registry status
Phase 1
Development phase
4
Enrollment target

NCT01276587 is a Phase 1 study that has completed, run by Gary M Brittenham, MD. The registered enrollment target is 4 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01276587, a Phase 1 study, has completed, sponsored by Gary M Brittenham, MD.

COMPLETED
Registry status
Phase 1
Development phase
4 participants
Enrollment target

Study Summary

This pilot study aims to answer the question whether monthly oral vitamin D3 supplementation, 100,000 IU, will be safe and effective in raising serum 25-hydroxyvitamin D (form of vitamin D measured in the blood) to levels considered sufficient (30 ng/mL) but well below the threshold for toxicity (150 ng/mL) in children with sickle cell disease. Information from this study will be crucial before we perform a larger clinical trial to determine the effects of vitamin D in reducing respiratory complications in patients with sickle cell disease.

Interventions

  • DRUG Vitamin D3

Trial Details

FieldValue
Enrollment Target 4 participants
Start Date 2011-01
Est. Completion 2011-06
Phase Phase 1

Sponsor

Gary M Brittenham, MD

2 total trials

What the Registry Record Tells You About NCT01276587

The ClinicalTrials.gov registry entry for NCT01276587 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gary M Brittenham, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Vitamin D3 is the first listed.

NCT01276587 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01276587 about?

NCT01276587 is a clinical study titled "Study of Vitamin D in Children With Sickle Cell Disease". This pilot study aims to answer the question whether monthly oral vitamin D3 supplementation, 100,000 IU, will be safe and effective in raising serum 25-hydroxyvitamin D (form of vitamin D measured in the blood) to levels considered sufficient (30 ng/mL) but well below the threshold for toxicity (15...

What is the current status of trial NCT01276587?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2011-01. Estimated completion is 2011-06.

What interventions are being tested in trial NCT01276587?

The interventions under investigation include: Vitamin D3 (DRUG).

Who is sponsoring clinical trial NCT01276587?

This trial is sponsored by Gary M Brittenham, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.